What are you looking for?

Category Archives: Uncategorized

We are Hiring – Operations Director

Who We Are – Ovagen Group Limited

We are an innovation based biotechnology company that has developed a proprietary process of producing the world’s first Germ Free eggs, for use in vaccine manufacture and other pharmaceutical and research applications. Germ free eggs are the highest quality products available to produce medicines like vaccines, reducing contamination and the need for antimicrobials, as well as improving sustainability and environmental impacts.  We also specialise in avian transgenic technology and we have a fully equipped transgenic laboratory.

As the first company in the world to produce commercial quantities of Germ Free eggs, from  our state-of-the-art avian facility, we have recently been awarded €10M funding by the European Commission and plans are in place to build two additional Germ Free production facilities and a logistics building, with which we will scale production to four million Germ Free eggs annually.

At Ovagen, we pride ourselves on scientific excellence, and we are passionate about the impact of our disruptive technology in transforming the way vaccines are produced to give security of supply and improve global immunisation coverage.

About the position

Our commercialisation plans are now being accelerated. Additionally, a series of studies over the next year are likely to show additional key advantages of Germ Free eggs, greatly increasing product demand.

This position of Operations Director is a key appointment and the successful candidate will report directly to our CEO in our HQ in the beautiful town of Ballina, County Mayo.

Key responsibilities include;

  • Managing the scale up of Ovagen’s production operation to support the Company in delivering on our ambitious plans to service the global vaccine industry.
  • Building, leading & developing a strong production operations team.
  • Ensuring that production is operating in accordance with best practice and in accordance with relevant regulations.
  • Ensuring that Germ Free egg production and shipments are delivered on time, to budget and in accordance with customer requirements.
  • Delivery on quality, efficiency and cost, whilst maintaining ‘Germ Free’ status.
  • Providing key operational and strategic input towards Ovagen’s business plan. This will include key operational input into our global expansion plans.
  • Supporting grant applications and financial management activities.
  • Representing the business at international conferences and client meetings.

The successful candidate will;

  • Have strong operational management experience in a highly regulated environment, preferably life sciences, and with a track record of success. 5 years +
  • Be educated to Degree level in an engineering, science or business related field.
  • Be comfortable managing all aspects of operations – from ground floor to board reporting.
  • Have strong leadership skills, including organisational development, team building, relationship building and effective stakeholder management.
  • Have excellent communication and interpersonal skills.
  • Have solid strategic and planning capability alongside a strong business acumen.

Whilst experience of operations in a Life Sciences facility is not a requirement, it would be a significant advantage.

What we Offer

This is a senior commercial and operational role, and the successful candidate will enjoy a generous package befitting of this.  This is an opportunity to join a positive and dynamic team at Ovagen Group, at an exciting time when we are poised and ready for growth.

If you are interested in applying to the role, please send your CV and covering letter to [email protected]

Ovagen Group Limited secures €10 million funding award from EIC Accelerator fund.


  • Second time in 3 years Ballina-based company has received EIC Accelerator funding
  • Follows the announcement of developing the world’s first bacteria free (‘germfree’) eggs in April.
  • Positions Ovagen as a potential world-leader in the production of germ-free eggs,

22nd June 2022, Ballina, Mayo, Ireland – Biotechnology company Ovagen Group Limited has again been awarded European Innovation Council (EIC) Accelerator funding, thanks to a €10 million funding award from the European Commission supported by the European Investment Bank (EIB), putting Ovagen in the top 7% of European companies who applied in this funding round.

The firm, which has its headquarters in Ballina in the west of Ireland, has been awarded a €2.5 million grant from the Horizon EIC Accelerator Programme, and a €7.5 million equity investment supported by the European Investment Bank. 

This latest grant from the EIC follows a €2.36M EIC grant which Ovagen was awarded in 2019.

“To receive funding at this significant level is a major endorsement of the value of Ovagen’s germ free eggs to the vaccine and biopharmaceutical industry, and of our strong track record of delivery on the previous EIC Grant,” Ovagen CEO and Co-Founder Dr. Catherine Caulfield, said. “Germ free eggs have been developed and are on the market, and this funding will allow us to demonstrate all their benefits and to scale-up and commercialise the business.”

Ovagen has developed the world’s first, bacteria free (‘germ free’), eggs.  Germ free eggs will be used in the production of human and animal vaccines, biotechnology applications and in cutting edge scientific research. Ovagen’s superior quality germ free eggs will set a new gold standard in the market and the biology of germ free eggs may also allow much greater viral yield to produce certain vaccines.

 “The EU funding is a game changer for Ovagen,” Ovagen Chairman, Chief Technical Officer and Co-Founder Dr. Leonard Moran said. “It has arrived at exactly the right time to allow us to scale up rapidly to meet customer demand with commercial production volumes.”

“This validates the 10 year’s research and development it has taken to get to this point,” Ovagen Senior Project Director Dr. Martin Murphy said. “but we now have the opportunity to impact millions of patient’s lives by supporting the production of better medicines”


About Ovagen Group Limited. Ballina, Mayo, Ireland.

Ovagen Group Limited is an innovation-based biotechnology company, led by experienced entrepreneurs, providing specialist contract products and services to the biopharmaceutical, pharmaceutical and vaccine industries. The company has developed a proprietary process of producing Germ Free chicken eggs and Germ Free birds in commercial quantities for use primarily in the pharmaceutical industry.

For more information, please contact:

Peg Connor (Administrative Office Manager):

Ovagen Receives a Second European Innovation Council (EIC) Grant

On 17th June 2022 Ovagen Group Ltd. was selected by the European Commission for €10M in grant and equity funding in what was the most competitive round of European Innovation Council (EIC) Accelerator funding to date, with only 7% of the over 1,000 companies across Europe being funded.  This is the second time Ovagen has been successfully awarded funding by the European Commission.  This award comprises of €2.5M grant from the EIC and €7.5M in equity supported by the European Investment Bank (EIB).  This funding will allow Ovagen provide scientific data to support key attributes of germ free eggs and to accelerate scale up of production and commercialisation.

You can read the full article from Enterprise Ireland by clicking here